Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Elicio Therapeutics is raising $8,411,801.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Connelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elicio Therapeutics

Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the brain center of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence.

To learn more about Elicio Therapeutics, visit http://elicio.com/

Contact:
Robert Connelly, Chief Executive Officer
857-209-0056
https://www.linkedin.com/in/robert-connelly-b0445516/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved